John G. Cox serves as the President and Chief Executive Officer of Dyne Therapeutics Inc., a biotechnology company focused on developing innovative treatments for genetically driven diseases. With a robust background in the pharmaceutical and biotechnology industries, Cox brings a wealth of experience and leadership to his role at Dyne. He joined the company in 2019 and has been instrumental in steering its strategic direction and growth. Under his leadership, Dyne has advanced its pipeline of therapeutic candidates, particularly in the area of muscle diseases, and has strengthened its position in the competitive biotech landscape. Before joining Dyne Therapeutics, Cox held several key positions that have shaped his career. He was the Chief Operating Officer at Receptos, where he played a pivotal role in the development and eventual acquisition of the company by Celgene for $7.2 billion. Prior to Receptos, Cox served as Senior Vice President of Corporate Development at Amgen, where he was responsible for numerous strategic initiatives and business development deals that significantly expanded the company’s portfolio. His expertise in corporate strategy, operations, and business development has been crucial in driving Dyne’s mission to bring transformative therapies to patients with serious muscle diseases. In his current role at Dyne Therapeutics, Cox oversees all aspects of the company’s operations, from research and development to commercialization efforts. His strategic vision has been key in forging partnerships and collaborations that have accelerated the development of Dyne’s therapeutic programs. Cox’s leadership is characterized by a commitment to scientific excellence and patient-centric innovation, which aligns with Dyne’s goal of making a meaningful difference in the lives of patients. His achievements and contributions continue to position Dyne as a leader in the field of genetic medicine.